Jonathon W. Senefeld,Patrick W. Johnson,Katie L. Kunze,Evan M. Bloch,Noud van Helmond,Michael A. Golafshar,Stephen A. Klassen,Allan M. Klompas,Matthew A. Sexton,Juan C. Diaz Soto,Brenda J. Grossman,Aaron A. R. Tobian,Ruchika Goel,Chad C. Wiggins,Katelyn A. Bruno,Camille M. van Buskirk,James R. Stubbs,Jeffrey L. Winters,Arturo Casadevall,Nigel S. Paneth,Beth H. Shaz,Molly M. Petersen,Bruce S. Sachais,Matthew R. Buras,Mikolaj A. Wieczorek,Benjamin Russoniello,Larry J. Dumont,Sarah E. Baker,Ralph R. Vassallo,John R. A. Shepherd,Pampee P. Young,Nicole C. Verdun,Peter Marks,N. Rebecca Haley,Robert F. Rea,Louis Katz,Vitaly Herasevich,Dan A. Waxman,Emily R. Whelan,Aviv Bergman,Andrew J. Clayburn,Mary Kathryn Grabowski,Kathryn F. Larson,Juan G. Ripoll,Kylie J. Andersen,Matthew N. P. Vogt,Joshua J. Dennis,Riley J. Regimbal,Philippe R. Bauer,Janis E. Blair,Zachary A. Buchholtz,Michaela C. Pletsch,Katherine Wright,Joel T. Greenshields,Michael J. Joyner,R. Scott Wright,Rickey E. Carter,DeLisa Fairweather,Noud van Helmond,Ruchika Goel,Arturo Casadevall,Benjamin Russoniello,Peter Marks,Louis Katz,Vitaly Herasevich,Aviv Bergman,Mary Kathryn Grabowski,Katherine Wright,DeLisa Fairweather

Abstract:Background The United States (US) Expanded Access Program (EAP) to coronavirus disease 2019 (COVID-19) convalescent plasma was initiated in response to the rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19. While randomized clinical trials were in various stages of development and enrollment, there was an urgent need for widespread access to potential therapeutic agents. The objective of this study is to report on the demographic, geographical, and chronological characteristics of patients in the EAP, and key safety metrics following transfusion of COVID-19 convalescent plasma. Methods and findings Mayo Clinic served as the central institutional review board for all participating facilities, and any US physician could participate as a local physician–principal investigator. Eligible patients were hospitalized, were aged 18 years or older, and had—or were at risk of progression to—severe or life-threatening COVID-19; eligible patients were enrolled through the EAP central website. Blood collection facilities rapidly implemented programs to collect convalescent plasma for hospitalized patients with COVID-19. Demographic and clinical characteristics of all enrolled patients in the EAP were summarized. Temporal patterns in access to COVID-19 convalescent plasma were investigated by comparing daily and weekly changes in EAP enrollment in response to changes in infection rate at the state level. Geographical analyses on access to convalescent plasma included assessing EAP enrollment in all national hospital referral regions, as well as assessing enrollment in metropolitan areas and less populated areas that did not have access to COVID-19 clinical trials. From April 3 to August 23, 2020, 105,717 hospitalized patients with severe or life-threatening COVID-19 were enrolled in the EAP. The majority of patients were 60 years of age or older (57.8%), were male (58.4%), and had overweight or obesity (83.8%). There was substantial inclusion of minorities and underserved populations: 46.4% of patients were of a race other than white, and 37.2% of patients were of Hispanic ethnicity. Chronologically and geographically, increases in the number of both enrollments and transfusions in the EAP closely followed confirmed infections across all 50 states. Nearly all national hospital referral regions enrolled and transfused patients in the EAP, including both in metropolitan and in less populated areas. The incidence of serious adverse events was objectively low (<1%), and the overall crude 30-day mortality rate was 25.2% (95% CI, 25.0% to 25.5%). This registry study was limited by the observational and pragmatic study design that did not include a control or comparator group; thus, the data should not be used to infer definitive treatment effects. Conclusions These results suggest that the EAP provided widespread access to COVID-19 convalescent plasma in all 50 states, including for underserved racial and ethnic minority populations. The study design of the EAP may serve as a model for future efforts when broad access to a treatment is needed in response to an emerging infectious disease. Trial registration ClinicalTrials.gov NCT#: NCT04338360 .

Access to COVID-19 Therapeutics in Long-Term Care Facilities- Public-Private Collaboration

Pharmacist interventions for appropriate COVID-19 antiviral therapy in long-term care facilities: A public health initiative

Providing COVID-19 Therapeutics and Clinical Guidance in Skilled Nursing Facilities

A Machine Learning Method for Allocating Scarce COVID-19 Monoclonal Antibodies

Challenges and opportunities during the COVID-19 vaccination efforts in long-term care

Advancing public health informatics during the COVID-19 pandemic: Lessons learned from a public–private partnership with pharmacies

A Framework for Outpatient Infusion of Antispike Monoclonal Antibodies to High-Risk Patients with Mild-to-Moderate Coronavirus Disease-19: The Mayo Clinic Model

Implementation of an Approach to Equitable Allocation of SARS-CoV-2 Monoclonal Antibodies for Pre-Exposure Prophylaxis: Experience from a Single Medical Center

Early COVID-19 First-Dose Vaccination Coverage Among Residents and Staff Members of Skilled Nursing Facilities Participating in the Pharmacy Partnership for Long-Term Care Program — United States, December 2020–January 2021

Monoclonal Antibody Infusions for Outpatient Management of Mild-Moderate COVID-19

The Power of Partnership: NYCEAL Collaborations With Health Agencies and Mobile Vaccination Vans

Early warning and rapid public health response to prevent COVID-19 outbreaks in long-term care facilities (LTCF) by monitoring SARS-CoV-2 RNA in LTCF site-specific sewage samples and assessment of antibodies response in this population: prospective study protocol

Novel approaches to enable equitable access to monoclonal antibodies in low- and middle-income countries

Implementation and Outcomes of Monoclonal Antibody Infusion for COVID-19 in an Inner-City Safety Net Hospital: A South-Bronx Experience

An Interprofessional Team for Disease-Modifying Therapy in Alzheimer Disease Implementation

Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study

A Framework for the Administration of Anti-amyloid Monoclonal Antibody Treatments in Early-Stage Alzheimer's Disease

The Influence of Social Determinants on Receiving Outpatient Treatment with Monoclonal Antibodies, Disease Risk, and Effectiveness for COVID-19

Health Equity and Access to COVID-19 Treatments Available through Emergency Use Authorizations

The role of funded partnerships in working towards decreasing COVID-19 vaccination disparities, United States, March 2021—December 2022

Monoclonal Antibody Therapy for COVID-19: A Retrospective Observational Study at a Regional Hospital